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cAMP Activates MAP Kinase and Elk-1
through a B-Raf- and Rap1-Dependent Pathway
Mark R. Vossler,1,2,3,8 Hong Yao,1,4,8 This action of NGF in these cells requires activation of
ERKs and induction of gene expression. ERKs regulateRandall D. York,1,5 Ming-Gui Pan,1
Caroline S. Rim,1 and Philip J. S. Stork1,6,7 gene expression, in part, through the phosphorylation
and activation of transcription factors of the Ets family,1Vollum Institute for Advanced Biomedical Research
2Division of Cardiology including Elk-1 (Marais et al., 1993). In PC12 cells, PKA
can induce morphological changes consistent with neu-3Department of Medicine
4Department of Molecular Microbiology ronal differentiation (Young et al., 1994), can potentiate
NGF's morphological effects during differentiation, andand Immunology
5Neuroscience Graduate Program can synergize with NGF in the induction of specific
genes (Heidemann et al., 1985; Yao et al., 1995). It is6Department of Pathology
7Department of Cell and Developmental Biology not known whether the differentiating actions of PKA
require ERKs, as has been reported for NGF (Cowley,Oregon Health Sciences University L-474
Portland, Oregon 97201 et al., 1994).
Potential mediators of cAMP's activation of ERKs in-
clude kinases that lie upstream along the MAP kinase
cascade (Frodin et al., 1994; Young et al., 1994). B-RafSummary
is abundantly expressed in the brain (Barnier et al, 1995)
and is activated in PC12 cells by Ras, following stimula-Cyclic adenosine monophosphate (cAMP) has tissue-
tion by NGF (Oshima et al., 1991) and epidermal growthspecific effects on growth, differentiation, and gene
factor (EGF) (Vaillancourt et al., 1994). Like Raf-1, theexpression. We show here that cAMP can activate the
activation of B-Raf by growth factors, as well as itstranscription factor Elk-1 and induce neuronal differ-
association with Ras, are inhibited by PKA (Wu et al.,entiation of PC12 cells via its activation of the MAP
1993; Moodie et al., 1994; Vaillancourt et al., 1994). How-kinase cascade. These cell type±specific actions of
ever, differences in the regulation of B-Raf and Raf-1cAMP require the expression of the serine/threonine
by cAMP have been proposed (Erhardt et al., 1995).kinase B-Raf and activation of the small G protein
Although Ras-dependent activation of B-Raf by growthRap1. Rap1, activated by mutation or by the cAMP-
factors can be blocked by cAMP, the ability of cAMPdependent protein kinase PKA, is a selective activator
to regulate B-Raf via Ras-independent pathways hasof B-Raf and an inhibitor of Raf-1. Therefore, in B-Raf-
not been characterized in detail. In this study, we soughtexpressing cells, the activation of Rap1 provides a
to examine the mechanisms by which cAMP activatesmechanism for tissue-specific regulation of cell growth
ERKs and Elk-1, and to ask whether this pathway de-and differentiation via MAP kinase.
pends on Ras or other small GTP-binding proteins.
B-Raf can be activated by the small G protein Rap1Introduction
in vitro (Ohtsuka et al., 1996). Rap1 is a member of the
Ras superfamily of GTP-binding proteins that sharesElevation of intracellular cAMP produces growth effects
50% amino acid sequence identity with Ras (Kitayamain a variety of cell types, including inhibition of growth
et al., 1990; Burgering and Bos, 1995), and, like Ras,factor±stimulated cell growth in fibroblasts (Rat-1 and
binds Raf isoforms in vitro and in vivo (Nassar et al.,NIH 3T3 cells), smooth muscle cells, and adipocytes.
1996). The GTP loading of Rap1 is stimulated by cAMPThe ability of growth factors to stimulate cell prolifera-
in vivo (Altschuler et al., 1995). Although it is likely thattion requires the small G protein Ras and MAP kinase or
GTP loading activates Rap1, in vivo effectors of Rap1ERK (extracellular signal±regulated kinases) (Marshall,
have not been defined. Instead, almost all of the actions1995). Ras activates the serine/threonine kinases Raf-1
of Rap identified, to date, involve the inhibition of Ras-and B-Raf (Lange-Carter et al., 1993; Vaillancourt et al.,
dependent signaling (Cook et al., 1993; Kitayama et al.,1994), which, in turn, activate the MAP kinase kinase,
1990). We show here that both PKA and Rap1 are selec-MEK, which then activates ERKs (Marshall, 1995). It has
tive activators of B-Raf in vivo and can activate selectedbeen proposed that the inhibitory effects of cAMP on
transcription factors and stimulate neuronal differen-cell growth reflect cAMP's inhibition of growth factor
tiation via an ERK-dependent, but Ras-independent,activation of ERKs (Cook and McCormick, 1993; Wu et
pathway.al., 1993). In other cell types, including PC12 cells, cAMP
does not antagonize the activation of ERKs by growth
factors, but activates ERKs (Frodin et al., 1994; Young Results
et al., 1994; Pan et al., 1995) and potentiates the effects
of growth factors on differentiation and gene expression cAMP Induces Neuronal Differentiation via ERKs
(Heidemann et al., 1985; Yao et al., 1995). cAMP's ability to differentiate PC12 cells was repro-
PC12 cells are derived from rat adrenal medullary cells duced by transfection of the catalytic subunit of PKA
and differentiate into sympathetic neurons upon treat- (cPKA) or treatment with the nonhydrolyzable cAMP an-
ment with nerve growth factor (NGF) (Marshall, 1995). alog 8-(4-chlorphenylthio)-cyclic AMP (8-CPT) (Figure
1). Cells transfected with cPKA were identified by co-
transfection with a cDNA encoding b-galactosidase8 These authors contributed equally to this work.
Cell
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Figure 1. ERK-Dependent and Ras-Independent Stimulation of Neurite Outgrowth in PC12 Cells by PKA
cPKA (10 mg) and RSV-b-gal (3 mg) were cotransfected into PC12 cells using lipofectamine (GIBCO/BRL). Cells transfected with RSV-b-gal
appear blue in this assay and cells cotransfected with PKA (A) develop neuritic processes. Cells transfected with vector and RSV-b-gal alone
remain undifferentiated (data not shown). Cells transfected with dnERKs (10 mg) (B) or MKP-2 (10 mg) (C) do not extend neurites in the presence
of 8-CPT, while untransfected cells treated with 8-CPT display neuritic processes. 8-CPT still stimulates neurite extension in cells transfected
with RasN17 (10 mg) (D). In contrast, RasN17 inhibits neurite outgrowth in cells treated with NGF (E). The percentage of neurites in b-gal1
cells is indicated in the lower right corner of each panel. The bar represents 10 mm.
(b-gal). Cells transfected with b-gal and treated with these signals appear to activate ERKs via Ras-depen-
dent mechanisms. Stimulation of myc-ERK2 by both8-CPT or NGF developed neurites in 63% and 75% of
b-gal1 cells, respectively (data not shown). These per- EGF and 8-CPT was completely blocked by expression
of dominant-negative MEK-1 (MEK-K97R) (Figure 2D).centages were not affected by cotransfection of plasmid
vector along with b-gal (Figure 7I). However, they were Therefore, like neuronal differentiation, cAMP's activa-
tion of MAP kinases requires MEK but is independentreduced by the expression of dominant-negative mu-
tants of the ERKs (dnERK1 and dnERK2; dnERKs) (Fig- of Ras.
ure 1B) and MKP-2 (Figure 1C), a MAP kinase phospha-
tase that is endogenously expressed in PC12 cells cAMP Activates Elk-1 via an ERK-Dependent,
(Misra-Press et al., 1995). The expression of the domi- Ras-Independent Mechanism
nant-negative mutant of Ras (RasN17) also blocked the Elk-1, a member of the Ets family of transcription factors,
ability of NGF (Figure 1E) to induce neurites but did not is an important physiological substrate of ERKs and
block neurite outgrowth induced by 8-CPT (Figure 1D). mediates serum-induced expression of immediate early
genes (Marais et al., 1993). The activation of ERKs was
also assayed indirectly by measuring the transactivationcAMP's Activation of ERKs Is Independent of Ras
of the 53 Gal4-E1b/luciferase reporter gene by anForskolin activated both ERK1 and ERK2 in PC12 cells
Elk-1/Gal4 chimera (Misra-Press et al., 1995). cAMP-(Figure 2A). This action was selective; neither forskolin
dependent Elk-1 activation was completely blocked bynor 8-CPT activated the related c-jun N-terminal kinases
dnERKs, but not by interfering mutants of JNKs (Figure(JNKs) (Figure 2B). ERK2 activity was also stimulated
2E), despite the ability of these mutants to block activa-by hormones and hormone analogs that are known
tion of c-jun (data not shown). Therefore, Elk-1activationactivators of adenylyl cyclase, including vasoactive-
is a useful measure of ERK activation by cAMP. Forsko-intestinal polypeptide (VIP) and isoproterenol (Figure
lin's activation of Elk-1 was blocked by the PKA inhibitor2C). ERK activation by these agents was inhibited by
PKI, demonstrating the requirement for PKA (Figure 2E).H-89 (N-[2-(p-bromocinnamylamino) ethyl]-5-isoquino-
Forskolin's activation of Elk-1 was also blocked signifi-line-sulfonamide), an inhibitor of PKA (Yao et al., 1995),
cantly by the expression of MEK-K97R but minimally bysuggesting that PKA was required for these hormonal
RasN17 (Figure 2E). As a control, we show that RasN17actions, as well. Epitope-taggedERK was used to exam-
can block activation of Elk-1 by NGF (Figure 2E, rightine the effect of transfected mutants on ERK activity.
panel). These data suggest that forskolin activates Elk-1,8-CPT's activation of transfected myc-ERK2 was not
as well as ERKs, at a level above MEK and downstreamblocked by expression of Ras N17, while EGF's activa-
of, or parallel to, Ras.tion was blocked (Figure 2D). Basal ERK activation was
also blocked by RasN17 to a similar degree as EGF-
stimulated ERK activity, suggesting that some constitu- cAMP Activates the Protein Kinase B-Raf
Upstream activators of MEK include Raf-1 and B-Raftive activation of upstream signaling cascades occurs
under basal conditions. Like signals generated by EGF, (Moodie et al., 1994). In PC12 cells, 8-CPT activated
PKA Activates ERKs via Rap1 and B-Raf
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Figure 2. Activation of ERKs and Elk-1 in
PC12 Cells by cAMP
(A) Activation of ERK1 and ERK2 by cAMP.
PC12 cells were treated with forskolin, NGF,
and EGF, alone or in combination, for 10 min,
and lysates immunoprecipitated using ERK1-
and ERK2-specific antibodies. Kinase assays
were performed as described. The position
of the ERK substrate, myelin basic protein
(MBP), is shown.
(B) Lack of stimulation of JNK activity by
cAMP. PC12 cells were treated with vehicle,
forskolin or 8-CPT for 10 min and lysed, or
with ultraviolet light (6J/m2 UVB) and lysed
60 min later, as indicated. JNK assays were
performed as described. The position of the
JNK substrate, gst-c-jun, is indicated.
(C) Activation of ERK2 by the cAMP analog,
8-CPT, the hormone VIP, and the b-adrener-
gic agonist isoproterenol in PC12 cells. Cells
were starved and pretreated with H-89 for 15
min or left untreated, then treated with VIP,
isoproterenol or 8-CPT for 10 min, as indi-
cated. ERK2 kinase assays were performed
as described. The position of MBP is shown.
(D) Ras independence of cAMP's stimulation
of ERKs. PC12 cells were transfected with
myc-ERK2 (5 mg) and either: upper gel,
pcDNA3 (10 mg); middle gel, RasN17 (10 mg);
lower gel, MEK-K97R (10 mg). Cells were
treated with EGF or 8-CPT or were left un-
treated, as indicated. Lysates containing 500
mg of total protein were immunoprecipitated
with the anti-myc 9E10 antibody and ERK
assays performed as above. Relative kinase
activities are shown (untreated cells trans-
fected with myc-ERK251). Equal levels of
myc-ERK2 expression in each transfectant
was confirmed by Western blotting, using
9E10 antibody (data not shown). This assay
was repeated three times with similar results.
(E) Activation of ERK-dependent gene transcription by cAMP. PC12 cells were transfected with 10 mg each of cDNAs encoding vector alone,
dominant-negative JNK (dnJNK), dnERKs, PKI, MEK K97R, or RasN17, and treated with forskolin or left untreated, as indicated. In addition,
all cells received 3 mg of Elk-1/Gal4, 3 mg of 53 Gal4-E1b luciferase, and 3 mg of CMV-CAT. Activation of Elk-1 is reflected by luciferase
activity and was reported as fold activation above basal normalized for CAT activity. Standard error is indicated (n 5 3). The bar graph at
right illustrates the requirement of Ras in NGF-mediated activation of Elk-1. Cells were transfected with vector or cDNA encoding RasN17
and treated with NGF. Luciferase assays of Elk-1 activity were performed as above. This serves as a control for the biological activity of the
RasN17 cDNA.
B-Raf (Figure 3A) but, like forskolin, inhibited Raf-1 activ- vator of Elk-1 (Figure 3D). Forskolin's ability to activate
Elk-1 also required transfection of B-Raf into these cells,ity (data not shown) (Vaillancourt et al., 1994). cAMP's
regulation of Raf isoforms resulted in changes in Elk-1 and this ability increased with increasing doses of B-Raf.
In contrast, forskolin inhibited the activation of Elk-1 byactivation. Transfection of B-Raf into PC12 cells in-
creased forskolin's activation of Elk-1. In contrast, for- Raf-1, at all doses examined (Figure 3E).
skolin's activation of Elk-1 was reduced following trans-
fection of Raf-1 (Figure 3B). The actions of transfected Rap1 Activates B-Raf and ERKs In Vivo
The mechanism by which cAMP induces Ras-indepen-B-Raf on cAMP signaling were more apparent in B-Raf-
deficient cells. B-Raf is expressed primarily in neuronal dent activation of B-Raf is not known. The small G pro-
tein, Rap1, is activated by cAMP in vivo (Altschuler etand endocrine cells (Barnier et al., 1995), and its expres-
sion was not detectable by immunoblot in NIH 3T3 fibro- al., 1995) and has been shown to activate B-Raf in vitro
(Ohtsuka et al., 1996). To ask whether B-Raf is a positiveblasts (Figure 3C). B-Raf activity has been detected in
NIH 3T3 cells by other techniques, suggesting that it is effector of Rap1 in vivo, we examined the actions of
RapV12, a constitutively activated mutant of Rap1 inexpressed, but at a much lower level than Raf-1 (Reuter
et al., 1995). To test the hypothesis that the expression which glycine at amino acid residue 12 is replaced with
valine within the GTPase domain. Like in the analogousof B-Raf dictates cAMP's activation of MAP kinase, we
introduced B-Raf into these cells. In the absence of Ras mutant, this results in increased GTP loading and
a prolonged activation state (Kitayama et al., 1990). InB-Raf, PKA was unable to activate Elk-1. However,
transfection of B-Raf converted PKA into a potent acti- contrast to its actions in other cell types, where it blocks
Cell
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Figure 4. Activation of ERKs in PC12 Cells by Constitutively Active
Rap1
(A) Stimulation of ERK2 activity by RapV12 and RapD179. Cells were
transfected with myc-ERK2 (5 mg) and RapV12 (10 mg), RasN17 (10
Figure 3. cAMP-Dependent Activation of Elk-1 Is Specifically Po- mg), MEK-K97R (10 mg), or RapD179 (10 mg), as indicated. Cells
tentiated by B-Raf were lysed, and transfected myc-ERK2 was immunoprecipitated
with 9E10 antibody. Assays of myc-ERK activity were performed as(A) Activation of B-Raf by 8-CPT and EGF in PC12 cells. Cells were
described in Figure 2. Equal levels of myc-ERK expression weretreated with 8-CPT or EGF, as indicated. B-Raf was immunoprecipi-
confirmed by Western blot using antibody 9E10 (data not shown).tated and its activity measured in vitro using MEK-1 as a substrate.
The results of a representative experiment are shown with relativeMEK-1 phosphorylation is indicated. The upper band corresponds
kinase activities provided above.to autophosphorylation of B-Raf. This result is representative of
(B) Requirement of MEK but not Ras for activation of Elk-1 bythree independent experiments.
RapV12. PC12 cells were transfected with cDNAs encoding Elk-1/(B) B-Raf and Raf-1 have opposing actions on forskolin-stimulated
Gal-4 and 53 Gal4-E1b/luciferase with 10 mg of either vector,Elk-1 activity in PC12 cells. PC12 cells were transfected with plas-
RapV12, RasN17, or MEK-K97R, alone or in combination, as indi-mids encoding either B-Raf (10 mg) or Raf-1 (10 mg) and Elk-1/
cated. Luciferase activity was assayed as described in Figure 2EGal-4 (3 mg) and 53 Gal4-E1b/luciferase (3 mg) plasmids and were
(n 5 3).subsequently treated with forskolin, as indicated. Elk-1 activation
(C) Requirement of Rap for cAMP-dependent activation of Elk-1.was monitored by luciferase activity. Standard error is as shown
PC12 cells were transfected with 3 mg each of Elk-1/Gal4 and 53(n 5 3).
Gal4-E1b/luciferase and 5, 10, or 15 mg of RapN17, as indicated.(C) B-Raf expression in PC12 cells and NIH 3T3 cells. B-Raf and
Cells were treated with forskolin (n 5 6) or EGF (n 5 3) as indicatedRaf-1 protein levels were determined by Western blot. 100 mg of
and luciferase assays performed as above.protein from whole cell lysates was analyzed by immunoblotting
(D) Activation of Elk-1 by Rap1, cAMP, and B-Raf. PC12 cells werewith B-Raf (left) and Raf-1 (right) antisera. Note that B-Raf was not
transfected with plasmids encoding 10 mg of either B-Raf, Rap1,detected in NIH 3T3 cells, and the 95 kDa form of B-Raf was the
or RapV12 and 3 mg of Elk-1/Gal-4 and 53 Gal4-E1b/luciferasepredominant form detected in PC12 cells. Raf-1 was expressed in
plasmids, and subsequently treated with forskolin (1 mM), as indi-both PC12 and NIH 3T3 cells.
cated. Elk-1 activation was monitored by luciferase activity (n 5 3).(D) Activation of Elk-1 in NIH 3T3 cells by cAMP following transfec-
tion of B-Raf. NIH 3T3 cells were transfectedwith plasmids encoding
B-Raf (8 mg) and/or cPKA (4 mg), as indicated along with Elk-1-
Gal-4 (5 mg) and 53 Gal4-E1b/luciferase (5 mg) plasmids. Elk-1 acti- Ras-dependent activation of MAP kinase (Cook and
vation was monitored by luciferase activity as in Figure 2E (n 5 3). McCormick, 1993), RapV12 stimulates ERKs and Elk-1
(E) Opposing actions of B-Raf and Raf-1 on cAMP's regulation of
in PC12 cells (Figures 4A and 4B). These effects wereElk-1. NIH 3T3 cells were transfected with Elk-1/Gal4 and 53 Gal4-
not blocked by RasN17 but were blocked by MEK-K97RE1B luciferase as in (D). Cells were cotransfected with increasing
(Figures 4A and 4B). Therefore, Rap1, like cAMP, acti-amounts of B-Raf (left graph) or Raf-1 (right graph) and were either
treated with forskolin or left untreated, as indicated. vates the ERK cascade via a pathway that is indepen-
dent of Ras but requires MEK. This action of RapV12
was selective for ERKs; it did not stimulate basal JNK
activity or potentiate JNK activity stimulated by other
PKA Activates ERKs via Rap1 and B-Raf
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agents (data not shown). These data confirm that Elk-1
activation by RapV12, like that of cAMP, is mediated by
the ERK cascade.
Rap1 is phosphorylated by PKA at a single site, serine
179, within its carboxyl terminus (Altschuler and Lapet-
ina, 1993). A role of PKA in Rap1's activation of ERKs
was suggested by the ability of RapD179 to activate
ERKs in this assay (Figure 4A). RapD179 encodes a
mutated Rap1 in which serine 179 was replaced with
an aspartic acid residue to mimic phosphorylation at
that position. Wild-type Rap1 had no effect in this assay
(data not shown).
The requirement for Rap1 in cAMP's activation of
Elk-1 was confirmed by using RapN17, a dominant-neg-
ative mutant corresponding to RasN17 (Stacy et al.,
1991). RapN17 blocked forskolin's activation of Elk-1
in PC12 cells. This inhibition was dose-dependent and
specific; activation by EGF was not blocked at any dose
(Figure 4C). These data demonstrate that endogenous
Rap1 is necessary for forskolin's effects on Elk-1. Ex-
pression of exogenous Rap1 could potentiate forskolin's
stimulation of Elk-1. In the absence of forskolin, wild-
type Rap1 was unable to activate Elk-1, but in the pres-
ence of B-Raf and low doses of forskolin (1 mM), Rap1
activated Elk-1 to levels greater than forskolin and B-Raf
alone (Figure 4D, right panel). In addition, transfection
of B-Raf greatly increased the activation of Elk-1 by
RapV12 in untreated PC12 cells (Figure 4D, left panel).
These results, and the results of Figure 3, demonstrate
that cAMP's activation of Elk-1 utilizes Rap1 and B-Raf.
Figure 5. Selective Stimulation of B-Raf by Rap1
(A) Kinase activity of B-Raf is potentiated by Rap1. COS-7 cellsRap1 Is a Selective Activator of B-Raf and Is
were transfected with cDNAs encoding B-Raf (16 mg), cPKA (4 mg),Required for PKA-Dependent B-Raf Activation
or Rap1 (16 mg) and treated with forskolin or vehicle, as indicated.
PKA and forskolin could also stimulate the activity of B-Raf activity was detected by immune complex assay, using re-
transfected B-Raf, when expressed at high levels in combinant MEK-1 as a substrate, as in Figure 3A (upper left gel).
COS-7 cells. Basal, forskolin- and PKA-stimulated B-Raf Control assays performed in the absence of MEK-1 showed no
kinase activity (data not shown). Immunoprecipitated B-Raf levelsactivities were augmented following the cotransfection
following each transfection were identical, as judged by Westernof wild-type Rap1 (Figure 5A). We confirmed that B-Raf
blot, using B-Raf antisera (lower left gel). The transfection of Rap1
activated by cAMP phosphorylates the sites in MEK-1 increased the kinase activity of transfected B-Raf in untreated cells
(serines 218 and 222) that have previously been shown and cells stimulated with either forskolin or PKA. Control assays
were performed using kinase-dead MEK (MKK8E) or the phosphory-to be required for MEK activation by Raf-1 (Alessi et al.,
lation site MEK mutant (MKK36A) as substrates (right gels).1994). MKK8, a kinase-inactive MEK that retains serines
(B) RapN17 selectively blocks activation of B-Raf by PKA, but not218 and 222 (Resing et al., 1995), is phosphorylated by
EGF. COS-7 cells were transfected with cDNAs encoding B-Raf (8
B-Raf coexpressed with PKA, while MKK36A, a MEK
mg), cPKA (4 mg), RapN17 (24 mg), or RasN17 (24 mg) and treated
mutant in which these serines are mutated to alanine, with or without EGF, as indicated. Following immunoprecipitation
with B-Raf antisera, B-Raf kinase assays were performed as de-is not phosphorylated (Figure 5A, right panel). Therefore,
scribed in Figure 3A. The expression of equal levels of transfectedthe results of the B-Raf kinase assays suggest that PKA
B-Raf was confirmed by Western blotting (data not shown).stimulates both the phosphorylation and activation of
(C) RapV12 selectively activates B-Raf in COS-7 cells. COS-7 cells
MEK via B-Raf. either were transfected with B-Raf (16 mg) and treated with 8-CPT
To determine whether Rap1 was required for PKA's or were cotransfected with RapV12. Parallel COS-7 cells either were
transfected with Raf-1 (16 mg) in the presence or absence of RapV12activation of B-Raf, we examined the action of RapN17
and treated with EGF or were cotransfected with RasV12 (16 mg),on B-Raf activity in COS-7 cells. RapN17 inhibited PKA's
as indicated. The kinase activities of B-Raf (left lanes) or Raf-1 (rightactivation of B-Raf, while B-Raf activity stimulated by
lanes) were measured as described, and the position of phosphory-
EGF was unaffected (Figure 5B). These studies demon- lated MEK-1 was indicated. The expression of equal levels of
strate that Rap1is required for PKA's activation of B-Raf. transfected Raf isoforms was confirmed by Western blotting (data
not shown).The strongest activator of B-Raf in COS-7 cells was
(D) Potentiation of RapV12 action by exogenous B-Raf and inhibitionRapV12 (Figure 5C). This activation was selective; Raf-1
of Raf-1 in NIH 3T3 cells. Cells were transfected with 16 mg ofwas not stimulated by RapV12. Furthermore, both EGF-
plasmids encoding B-Raf or Raf-1 and 4 mg RapV12, as indicated,
and RasV12-stimulated Raf-1 kinase activity were inhib- in the presence of 5 mg each of Elk-1/Gal-4 and 53 Gal4-E1b/
ited by RapV12 (Figure 5C). Therefore, Rap1 is a selec- luciferase. Luciferase assays were performed as previously de-
scribed (n 5 3).tive activator of B-Raf and inhibitor of Raf-1.
Cell
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B-Raf Can Convert Rap1 into an Activator of Elk-1
To test the hypothesis that the expression of B-Raf per-
mits RapV12, as well as PKA, to activate the MAP kinase
cascade, we transfected NIH 3T3 cells with either B-Raf
or Raf-1 and examined Elk-1 activation by RapV12.
RapV12 activation of Elk-1 was greatly potentiated by
cotransfecting B-Raf. The expression of B-Raf alone, in
the absence of RapV12, had no effect on Elk-1. In con-
trast, Raf-1 activation of Elk-1 was completely blocked
by RapV12 (Figure 5D). Therefore, like PKA, RapV12
selectively activates B-Raf in multiple cells. The small
amount of activation of Elk-1 following transfection of
RapV12 alone may reflect low endogenous levels of
B-Raf in these cells (Reuter et al., 1995) or the presence
of additional unidentified targets of Rap1.
cAMP Stimulates GTP Loading of Rap1
in PC12 Cells
PC12 cells express abundant Rap1 protein that was
phosphorylated in response to forskolin treatment (Fig- Figure 6. Phosphorylation, GTP Loading, and Coprecipitation of
ure 6A). This phosphorylation is associated with in- Rap Proteins
creased GTP loading of Rap1 in these cells (Figure 6B), (A) Phosphorylation of Rap1 in forskolin-treated PC12 cells. Cells
as has been shown in other cell types (Hata et al., 1991; were metabolically labeled with [32P]-orthophosphate and treated
with forskolin (50 mM) and IBMX (10 mM) as indicated. Lysates wereAltschuler et al., 1995). In contrast, EGF had no effect
prepared as described, and Rap1 was immunoprecipitated with oron GTP loading of Rap1 in these cells (Figure 6B).
without antibody, as indicated. Immunoprecipitated proteins were
resolved using 12% SDS±PAGE and visualized by autoradiography.
PKA Induces the Association of B-Raf (B) Rap1 activation by 8-CPT. GTP loading was assayed in PC12
and Rap1 in PC12 Membranes cells following transfection of His-Rap (30 mg). PC12 cells were left
In PC12 cells, Rap1 and B-Raf are localized to the cell untreated (U) or were treated with EGF or 8-CPT for 5 min, as indi-
cated. His-Rap was precipitated with Ni-NTA-Agarose, and eluatesmembrane and cytosol, respectively (data not shown).
were analyzed for GTP and GDP content by thin-layer chromatogra-8-CPT stimulated the association of B-Raf with Rap1
phy. The GTP fraction of total guanine nucleotide is given abovewithin membranes (Figure 6C). This action was specific
each lane.
for both cAMP and Rap1; no association of B-Raf with (C) 8-CPT, but not EGF, induces the association of Rap1 with B-Raf
Rap1 was detected within membranes following treat- within membranes. Membranes and cytosolic fractions were pre-
ment with EGF or in untreated cells (Figure 6C), nor pared from PC12 cells treated with 8-CPT or EGF or left untreated
(2), as indicated. Lysates were immunoprecipitated with Rap anti-was B-Raf detected in immunoprecipitates using Ras
sera and probed by Western blot using B-Raf antisera. The migrationantibody Y13-238 (data not shown). Parallel Western
of B-Raf in PC12 lysates is shown in the right lane. The band corre-blots were performed to confirm the ability to immuno-
sponding to the IgG heavy chain is indicated.
precipitate both Ras and Rap1 (data not shown). (D) GTP dependence of the association of B-Raf kinase activity with
The GTP dependence of this interaction was exam- Rap1. COS-7 cells were transfected with 10 mg of His-Rap, 12 mg
ined in COS-7 cells transfected with B-Raf and 63 histi- of B-Raf, 5 mg PKA, or 10 mg of His-RapV12, as indicated. His-Rap
proteins were precipitated with Ni-NTA-Agarose, and associateddine-tagged Rap1b (His-Rap) or His-RapV12. Rap and
B-Raf kinase activity was immunoprecipitated with B-Raf anti-Rap-associated proteins were purified using Nickel af-
sera and kinase assays performed as previously described (upperfinity. B-Raf and its kinase activity were detected in
gel). The position of MEK-1 is shown. Associated B-Raf was also
eluates (Figure 6D). The small amount of B-Raf associat- detected by Western blotting. The position of B-Raf is shown
ing with His-Rap1 was increased in cells cotransfected (lower gel).
with PKA. The highest level of B-Raf was detected in
cells cotransfected with His-RapV12 (Figure 6D, lower RapV12-transfected cells developing neurites was simi-
gel). Only eluates from B-Raf-transfected cells con- lar to that in cells transfected with RasV12 (Figures 7A±
tained B-Raf activity, as measured by immune complex 7C). This action of RapV12 was completely blocked by
assay using B-Raf antisera. B-Raf activity associated MEK-K97R, but was only modestly blocked by RasN17
with His-Rap1 was greatly stimulated by PKA, to a level (Figures 7D±7F). Cotransfection of these mutants did
similar to that associating with His-RapV12 (Figure 6D, not alter the level of expression of transfected Rap pro-
upper gel). The expression of equal amounts of His-Rap tein as confirmed by Western blotting (data not shown).
was confirmed by immunoblotting with Rap1 antisera RapN17 (Figures 7G and 7H), but not vector control
(data not shown). These data suggest that the associa- (Figure 7I), interfered with the ability of 8-CPT, but not
tion of activated B-Raf protein with Rap1 is increased NGF, to differentiate these cells. These data demon-
upon GTP loading, stimulated by PKA or by a V12 mu- strate that Rap1 is required for cAMP-dependent differ-
tation. entiation of PC12 cells.
Constitutively Active Rap Stimulates Neuronal Discussion
Differentiation in PC12 Cells
Transfection of RapV12, but not vector alone, induced We demonstrate that B-Raf can convert cAMP into an
activator of ERKs and Elk-1. The action of cAMP onneurite outgrowth in PC12 cells. The percentage of the
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68 kDa. The majority of B-Raf expressed in those cells
was a 68 kDa form, while only the minor 95 kDa form
was shown to be activated by growth factors (Lange-
Carter et al., 1993; Vaillancourt et al., 1994). In contrast,
the PC12 cells used in this study express predominantly
the 95 kDaform (Figure 3C). The inability of 68 kDa forms
to be activated by growth factors may also account for
the finding that cAMP's ability to activate ERKs does
not correlate with the expression of the lower molecular
weight forms of B-Raf (Faure and Bourne, 1995).
cAMP Induces Activation of ERKs and Neuronal
Differentiation via a Rap-Dependent,
Ras-Independent Pathway
We show that cAMP's activation of ERKs, as well as
the induction of neurite outgrowth by both cAMP and
RapV12, is largely independent of Ras but requires
Rap1. However, cells expressing both RapV12 and
RasN17 showed decreased neurite length compared
Figure 7. Stimulation of Neurite Outgrowth in PC12 Cells by RapV12 with RapV12alone (Figure7D), suggesting that complete
RapV12 (5 mg) or RasV12 (5 mg) and RSV-b-gal (3 mg) were cotrans- differentiation by Rap may require additional Ras-
fected into PC12 cells using lipofectamine (GIBCO/BRL). Trans- dependent pathways (Frech, et al., 1990).
fected cells appear blue in this assay. Cells transfected with vector The ability of cAMP, like that of NGF, to induce differ-
and RSV-b-gal alone (A) remain undifferentiated, while cells receiv-
entiation in these cells may require sustained activationing RasV12 (B) or RapV12 (C) develop processes. Cells were
of ERKs (Cowley et al., 1994; Young et al., 1994). Agentstransfected with RapV12, RSV-b-gal, and either RasN17 (D), MEK
like EGF, that activate ERKs transiently, are unable toK97R (E), or dnERKs (F). RapV12-induced neurites were blocked
by MEK K97R and dnERKs, but not by RasN17. Cells were either differentiate PC12 cells (Cowley et al., 1994). EGF's acti-
transfected with RapN17 and RSV- b-gal and treated with 8-CPT vation of ERKs is terminated, in part, via the direct phos-
(G) or NGF (H) or transfected with RSV-b-gal, in the presence of phorylation of theRas guanine nucleotide exchange fac-
vector control, and treated with 8-CPT (I). Differentiation by 8-CPT
tor SOSby the ERKs themselves (Porfiri and McCormick,(G), but not NGF (H), was blocked by RapN17. Transfection of RSV-
1996). We show that cAMP's ability to differentiate PC12b-gal and vector alone had no effect on the percentage of 8-CPT-
cells requires Rap1 but not Ras. cAMP's ability to acti-induced neurites (I). The percentages of b-gal1 cells with neurites
are indicated. vate Rap1 and ERKs via a Ras-independent mechanism
may bypass this negative feedback loop regulating Ras-
dependent signaling, to permit cAMP to induce sus-
B-Raf is the opposite of its action on Raf-1 (Wu et al.,
tained activation of ERKs associated with differentiation
1993; Burgering and Bos, 1995). Unlike cAMP's inhibi-
in these cells.
tion of growth factor activation of B-Raf, where cAMP
blocks Ras-dependent pathways (Vaillancourt, et al.,
1994), cAMP's activation of B-Raf utilizes the small G Rap1 Is a Selective Activator of B-Raf
The specificity of cAMP for B-Raf is reflected in theprotein Rap1. Rap1, like cAMP, activates B-Raf and
inhibits Raf-1. Therefore, in cells that express B-Raf and actions of Rap1 on B-Raf. We demonstrate that Rap1
is a selective activator of B-Raf and that B-Raf canRaf-1, cAMP's actions onERKs may represent a balance
between its effects on each Raf isoform. convert Rap1 and cAMP into activators of ERKs and
Elk-1. In contrast, Ras can activate all known Raf iso-
forms. We show here that Rap1 activates B-Raf andcAMP Activates B-Raf in PC12 Cells
and Transfected COS-7 Cells inhibits Raf-1. Therefore, despite its initial characteriza-
tion as an antagonist of Ras, Rap1 may activate MAPAlthough cAMP can antagonize Ras-dependent activa-
tion of B-Raf, cAMP's regulation of B-Raf activity has kinase in B-Raf-expressing cells. This may explain the
mitogenic effects of Rap1 in Swiss3T3 cells (Yoshida etnot been examined independently of Ras activation
(Vaillancourt et al., 1994; Erhardt et al., 1995). We show al., 1992; Faure and Bourne, 1995). The ability of B-Raf
to convert inhibitory PKA signals into stimulatory onesthat cAMP can activate B-Raf in PC12 cells in the ab-
sence of factors that activate Ras and that both cAMP may identify a novel role for B-Raf during development
of hormonally responsive tissues.and PKA can stimulate B-Raf following transfection in
COS-7 cells. This MEK kinase activity of B-Raf is limited We show that the actions of cAMP on B-Raf are medi-
ated by PKA's activation of Rap1. Both PKA activationto serines 218 and 222, sites responsible for the activa-
tion of MEK by Raf-1 (Alessi et al., 1994; Resing et al., and GTP loadingof Rap1 induce theassociation of B-Raf
with Rap1. It is possible that B-Raf may be activated by1995). Therefore, PKA stimulates both the phosphoryla-
tion and activation of MEK via B-Raf. recruitment to membranes (Figure 6C) to form a complex
with Rap1 in a manner similar to that shown for Raf-1cAMP's activation of B-Raf and ERKs may depend
on the cell lines examined. For example, one previous activation by Ras (Hallberg et al., 1994; Leevers et al.,
1994; Marshall, 1995). In some cells, the ability to detectstudy was unable to detect activation of B-Raf or ERKs
by cAMP (Vaillancourt et al., 1994). The cells used in an association between endogenous Raf-1 and Ras pro-
teins is limited, suggesting that the interaction betweenthat study expressed two forms of B-Raf, 95 kDa and
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hr at 378C in 5% CO2 prior to treatment with forskolin (10 mM),Raf-1 and Ras is transient (Leevers et al., 1994). Differ-
8-CPT (175 mM), NGF (100 ng/ml), EGF (50 ng/ml), VIP (10 mM), orences in the activation of B-Raf and Raf-1 by Ras have
isoproterenol (10 mM), unless otherwise indicated.been proposed (Yamamori et al., 1995; Jaiswal et al.,
1996; Okada et al., 1996). Therefore, the differences in Immune Complex Assays
the ability to detect the association of endogenous Cells were grown to 50% confluence, serum-starved for 16 hr, and
B-Raf with Rap1 and Ras may reflect biochemical differ- treated with agents as indicated. ERK assays were performed using
myelin basic protein (MBP) and [32P]-gATP as substrates, as de-ences between the Raf isoforms, as well as differences
scribed (Pan, et al., 1995). JNK assays were performed using c-junbetween Ras and Rap1 (Kuroda et al., 1996).
and [32P]P-gATP as substrates, as described (DeÂ rijard et al., 1994).The ability of RapN17 to inhibit cAMP's activation of
For Raf assays, untreated and treated cells were lysed in 1% NP-40
B-Raf, ERKs, and differentiation in PC12 cells suggests buffer containing 10 mM Tris (pH 7.4), 5 mM EDTA, 50 mM NaCl,
that a Rap-GEF may berequired for each of these effects and 1 mM PMSF. Immune complex kinase assays were performed
of cAMP (Stacy et al., 1991). PKA increases the GTP as described, using MEK-1 and [32P]P-gATP as substrates (Vaillan-
court et al., 1994). The reaction products of all kinase assays wereloading of Rap1 and phosphorylates Rap at a single site
resolved by 10% SDS±polyacrylamide gel and analyzed with a Phos-(Altschuler and Lapetina, 1993; Altschuler et al., 1995).
phorImager (Molecular Dynamics). Transfection of B-Raf into COS-7A possible relationship between these two actions is
cells was required to detect B-Raf activity, consistent with the low
suggested by the constitutive activation of ERKs by levels of endogenous B-Raf expressed in these cells (Faure
RapD179, a mutant that mimics this phosphorylation in and Bourne, 1995).
Rap1. It has been previously shown that phosphoryla-
tion at this site may potentiate the actions of a Rap- Construction of Expression Vectors
Wild-type Rap1b was cloned by PCR from a bovine brain cDNAspecific GEF, Smg-GDS, in vitro (Hata et al., 1991). The
library, using specific primers to the published Rap1b sequence:requirement for this phosphorylation in Rap1 activation
(sense oligo: GGCAAGCTTGAGACCATGCGTGAGTATAAGCTAGTin vivo has not been demonstrated, making it possible
and antisense oligo: GGCGAATTCTATTAAAGCAGTGACATGAT
that phosphorylation may lead to activation of Rap GACT), and subcloned into pcDNA3 (Invitrogen). RapV12 was con-
through other mechanisms and that PKA may have addi- structed following PCR amplification of the full-length clone, using
tional substrates to account for cAMP's activation of a mutant 59 oligonucleotide primer (sense oligo: GGCGGATCCATGC
GTGAGTATAAGCTATCGTTCTTGGCTCTGTAGGCCTT) resulting inRap1 in PC12 cells.
a valine for glycine substitution at amino acid 12, and subcloned intoOther activators of Rap1 may stimulate B-Raf and
pcDNA3. RapD179 was constructed following PCR amplificationERKs as well. Recently, an association between the
of the full-length clone, using a mutant 39 oligonucleotide primer:
SH2-containing adapter protein Crk and a Rap1 activa- (antisense oligo: GGCGAATTCTATTAAAGCAGCTGACATGAGTCCT
tor, C3G, was identified (Gotoh et al., 1995). However, TTTTGCGGGCCTTC) resulting in an aspartic acid-for-serine substi-
the expression of C3G does not appear to potentiate tution at amino acid 179.
RapN17 was constructed following PCR amplification of the full-cAMP's activation of ERKs (data not shown), suggesting
length clone, using a mutant sense oligonucleotide primer: GGCGGAthat C3G may respond to other factors, including Crk
TCCGAGACCATGCGTGAGTATAAGCTAGTCGTTCTTGGCTCTGGAitself. In addition, the calcium- and calmodulin-depen-
GGCGTTGGAAAAAATGCTCTG ACTGTA.
dent protein kinase (CaM kinase) IV can phosphorylate His-Rap (wild-type) and His-RapV12 were constructed by ampli-
Rap1 in vitro (Sahyoun et al., 1991) at the same site fying the corresponding Rap sequences with a 59 oligonucleotide
that has been shown to be phosphorylated by PKA encoding a Kozak recognition site, start codon, and poly-Histidine
sequence in-frame with the second amino acid of the Rap coding(Altschuler and Lapetina, 1993). Therefore, in B-Raf-
region (sense oligo: ACCGAGCTCGGATCCATGGGACATCACCACCexpressing cells, Rap1 has the potential to integrate the
ACCACCACAGCGG GAATTCTCGTGAGTATAAG). The resultant am-actions of diverse signals to dictate cellular responses
plification products were subcloned into pcDNA3 (Invitrogen) and
governing growth and differentiation. sequenced.
Experimental Procedures Plasmids and Transfection
All cell lines were grown to 50% confluence prior to transfection.
Materials Unless otherwise indicated, transfections were performed using cal-
Agarose-conjugated ERK1, ERK2, and JNK1 antibodies were pur- cium phosphate per the instructions of the manufacturer (GIBCO-
chased from Santa Cruz Biotechnology Inc. Polyclonal anti-Rap1 BRL). In all experiments, total DNA transfected was kept constant
[Krev-1(121)], anti-Raf-1 (C-12), anti-B-Raf (C-19), Ras monoclonal with addition of pcDNA3 vector. For luciferase assays, 53 Gal4-
antibodies (Y13-259 and Y13-238), Gst-c-jun and MEK-1 protein E1b/luciferase and a plasmid encoding the Gal4-Elk1 or Gal4-c-
were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, jun transactivation domain were used in combination with other
CA.) Anti-myc antibody 9E10 (provided by A. Shaw, Washington plasmids as indicated. MEK K97R (gift of K-L. Guan, University of
University, St. Louis, MO) was used to immunoprecipitate exoge- Michigan) was subcloned into pcDNA3. RasV12, Elk-1/Gal-4, 53
nous Myc-ERK2 fusion protein. MKK 8E and MKK 36A were provided Gal4-E1b/luciferase, cPKA, and PKI were gifts of R. Maurer, OHSU;
by N. Ahn (University of Colorado, Boulder, CO). Nickel agarose (Ni- RasN17 (Stacy et al., 1991) was provided by N. Nathanson, Univer-
NTA-Agarose) was purchased from Qiagen Inc. (Chatsworth, CA.). sity of Washington; MEKKD was provided by G. Johnson, National
Radioisotopes were from NEN-DuPont. All other reagents were from Jewish Hospital; and Gal4-c-jun was provided by R. Goodman, Vol-
Sigma (St. Louis, MO). lum Institute. cDNA encoding Raf-1was provided by A. Shaw, Wash-
ington University; dominant-negative (dn) mutants of ERK1 and
ERK2 were provided by M. Cobb, University of Texas, Southwest-Cell Culture
PC12-GR5 cells were provided by R. Nishi (Oregon Health Sciences ern); dnJNK was provided by R. Davis, University of Massachusetts;
myc-ERK2 and pEXV3 MAPKK1 (Cowley et al., 1994) were providedUniversity, Portland, OR) and were maintained in DMEM (Dulbecco-
Modified Eagle Medium) plus 10% horse serum and 5% fetal calf by C. Marshall, Chester Beatty Institute for Cancer Research, Lon-
don; and C3G was provided by M. Matsuda, National Institute ofserum on 100 mm plates to 70±80% confluence prior to harvesting.
COS cells and NIH 3T3 cells were maintained in DMEM plus 10% Health, Tokyo. CMV-CAT was transfected as an internal control for
gene expression. Cells were transfected as described and treatedfetal calf serum. For immune complex assays and Western blotting,
the cells were deprived of serum and maintained in DMEM for 16 with forskolin, 8-CPT, or growth factors. After 6 hr of treatment,
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